ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

bempedoic acid

Also written as “ETC-1002”, “Bempedoic acid” and “180mg of ETC-1002(bempedoic acid)”.

Its studies are mostly in Hypercholesterolemia · Hyperlipidemias · Dyslipidemias · Coronary Artery Disease · Hyperlipoproteinemia Type II, led by 6 companies.

Drug pageBempedoic acid: every studyMany companies study it; this page follows only the 33 they lead. All 43 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Aug 27, 202333 company-led studies, 2 open or runningNext primary completion: Jun 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Esperion Therapeuticsits history only200 open or runningphase 4since Aug 27, 2023Dec 16, 2010none ahead
Daiichi Sankyoits history only61 open or runningphase 4since Apr 6, 2025Apr 6, 2025Jun 1, 2028phase 3 · NCT07474649
Otsukaits history only30 open or runningphase 3since Jan 4, 2023Mar 2, 2021none ahead
Humanis Saglık Anonim Sirketiits history only20 open or runningphase 1since Apr 4, 2025Apr 4, 2025none ahead
CSPC Pharmaceutical Groupits history only11 open or runningphase 3since May 29, 2026May 29, 2026Jun 30, 2027phase 3 · NCT07623915
Gan & Lee Pharmaceuticals10 open or runningphase 3since Jan 13, 2025Jan 13, 2025none ahead

Also a collaborator on its studies: Medpace.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 13, 2025First study: phase 3 study in HyperlipidemiasFirst studyNCT06780410 · 245 enrolled · China

TargetBeta

ACLY →read by rule
“An orally bioavailable prodrug and inhibitor of adenosine triphosphate-citrate lyase (ACL), with anti-hyperlipidemic activity”NCIt, by rule
“ATP-citrate synthase inhibitor”ChEMBL 37, by rule

Studies

The one study Gan & Lee Pharmaceuticals leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06780410Hyperlipidemias · China3CompletedAug 5, 2025245

How it is read

Names in the registry

  • “ETC-1002”, 10 entries
  • “Bempedoic acid”, 7 entries
  • “180mg of ETC-1002(bempedoic acid)”, 3 entries
  • “bempedoic acid”, 3 entries
  • “Bempedoic Acid Tablet”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.